Lantheus Medical Imaging Inc (Lantheus Medical), a subsidiary of Lantheus Holdings, Inc., develops, manufactures and commercializes diagnostic imaging agents and products. The company offers commercial products including ultrasound contrast agent and medical radiopharmaceuticals in a range of imaging modalities. Its products include DEFINITY, TechneLite, Xenon 133, Neurolite, , Thallium-201, Cardiolite and Gallium-67. The company’s product pipeline include 1095 and LMI 1195. The company offers its products to nuclear physicians, internal medicine physicians, radiologists, technologists and sonographers, integrated delivery networks, hospitals, clinics and group practices. Lantheus Medical is headquartered in North Billerica, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Lantheus Medical Imaging Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Lantheus Medical Imaging Inc Company Overview
- Lantheus Medical Imaging Inc Company Snapshot
- Lantheus Medical Imaging Inc Pipeline Products and Ongoing Clinical Trials Overview
- Lantheus Medical Imaging Inc - Pipeline Analysis Overview
- Business Description
- Lantheus Medical Imaging Inc - Key Facts
- Lantheus Medical Imaging Inc - Major Products and Services
- Lantheus Medical Imaging Inc Pipeline Products by Development Stage
- Lantheus Medical Imaging Inc Ongoing Clinical Trials by Trial Status
- Lantheus Medical Imaging Inc Pipeline Products Overview
- Flurpiridaz F 18
- Flurpiridaz F 18 Product Overview
- LMI 1174
- LMI 1174 Product Overview
- LMI 1195
- LMI 1195 Product Overview
- Pylarify
- Pylarify Product Overview
- Pylarify Clinical Trial
- RP782
- RP782 Product Overview
- Lantheus Medical Imaging Inc - Key Competitors
- Lantheus Medical Imaging Inc - Key Employees
- Lantheus Medical Imaging Inc - Key Employee Biographies
- Lantheus Medical Imaging Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- Lantheus Medical Imaging Inc, Recent Developments
- Feb 03, 2020: Lantheus announces topline results for BENEFIT 1 LVEF clinical trial
- Dec 10, 2019: Lantheus, CarThera to use microbubble for glioblastoma treatment
- Oct 31, 2019: Bristol-Myers Squibb reports third quarter 2019 financial results
- Jun 24, 2019: Lantheus announces presentation of new patient outcomes data for DEFINITY at the American Society of Echocardiography 2019 Annual Scientific Sessions
- Jun 20, 2019: Lantheus announces new patient outcomes data for DEFINITY to be presented at the American Society of Echocardiography 2019 Annual Scientific Sessions
- Sep 17, 2018: Medical Society files FDA citizen petition seeking removal of boxed warnings on ultrasound contrast agents
- Aug 30, 2018: Lantheus Holdings appoints Etienne Montagut as senior vice president of corporate development
- Aug 20, 2018: Lantheus Holdings names Robert J. Marshall, Jr. as Chief Financial Officer and Treasurer
- Aug 02, 2018: GE Healthcare initiates new Phase III trial of Flurpiridaz to detect CAD
- May 02, 2018: Lantheus Holdings Announces 2018 First Quarter Financial Results
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Lantheus Medical Imaging Inc Pipeline Products and Ongoing Clinical Trials Overview
- Lantheus Medical Imaging Inc Pipeline Products by Equipment Type
- Lantheus Medical Imaging Inc Pipeline Products by Indication
- Lantheus Medical Imaging Inc Ongoing Clinical Trials by Trial Status
- Lantheus Medical Imaging Inc, Key Facts
- Lantheus Medical Imaging Inc, Major Products and Services
- Lantheus Medical Imaging Inc Number of Pipeline Products by Development Stage
- Lantheus Medical Imaging Inc Pipeline Products Summary by Development Stage
- Lantheus Medical Imaging Inc Ongoing Clinical Trials by Trial Status
- Lantheus Medical Imaging Inc Ongoing Clinical Trials Summary
- Flurpiridaz F 18 - Product Status
- Flurpiridaz F 18 - Product Description
- LMI 1174 - Product Status
- LMI 1174 - Product Description
- LMI 1195 - Product Status
- LMI 1195 - Product Description
- Pylarify - Product Status
- Pylarify - Product Description
- Pylarify - 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
- Pylarify - A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination with Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who are 18F-DCFPyL Prostate-specific Membrane Antigen (PSMA)-Avid, Chemotherapy-naive, and Progressed on Abiraterone
- Pylarify - A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
- Pylarify - A Prospective Observational Multicenter Real-World Registry Assessing the Impact of the Use of PYLARIFY (Piflufolastat F18) PET in Patients With Prostate Cancer
- Pylarify - A Study of Prospective Monitoring of Subjects with Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL
- Pylarify - Hepatocellular Carcinoma Imaging Using PSMA PET/CT - a Prospective Pilot Trial
- Pylarify - Monitoring Prostate Cancer Tumor Response to Radiation Therapy Using Advanced Functional Magnetic Resonance Imaging (MRI) and Pylarify (18F-DCFPyL) PSMA Positron Emission Tomography (PET)
- Pylarify - Phase II Study to Evaluate the Performance of PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Clinically Significant Prostate Cancer in Men Presenting Following a Positive Screen for Prostate Cancer
- Pylarify - Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
- Pylarify - Pre-operative Localization of Parathyroid Adenomas Using F-18 PSMA PET/CT: A Pilot Study
- Pylarify - Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
- Pylarify - Prostate Specific Membrane Antigen (PSMA) Scan and Multiparametric MRI for Prostate Biopsy Detection of Clinically Significant Prostate Cancer
- Pylarify - The Utility of PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men with High GC Decipher Test Scores: A Sub-aim of the VANDAAM Study (MCC #18523)
- RP782 - Product Status
- RP782 - Product Description
- Lantheus Medical Imaging Inc, Key Employees
- Lantheus Medical Imaging Inc, Key Employee Biographies
- Glossary
- Lantheus Medical Imaging Inc Pipeline Products by Equipment Type
- Lantheus Medical Imaging Inc Pipeline Products by Development Stage
- Lantheus Medical Imaging Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AngioDynamics Inc
- Bracco Diagnostics Inc
- GE HealthCare Technologies Inc
- RadNet Inc
- RedHill Biopharma Ltd
